TABLE 5

Effects of Changes in Therapy and Neonatal Risk Factors Between Period I and Period II on Outcomes for Birth Weight-Specific Cohort (Birth Weight of <1000 g)

Odds Ratio (95% Confidence Interval)
MDI of <70Neurosensory AbnormalityaNeurodevelopmental Impairmentb
Period (I versus II)1.13 (0.56–2.29)0.62 (0.25–1.56)1.12 (0.54–2.34)
Maternal education less than high school2.11 (0.96–4.64)0.96 (0.34–2.74)1.48 (0.66–3.32)
Race1.53 (0.83–2.84)1.69 (0.89–3.19)
Gender1.29 (0.72–2.31)0.92 (0.50–1.68)
Multiple birth2.18 (0.95–5.01)2.10 (0.77–5.71)2.90 (1.22–6.90)c
Prenatal steroid therapy0.72 (0.37–1.42)0.82 (0.35–1.90)0.65 (0.32–1.30)
Duration of ventilator dependence1.02 (1.01–1.04)d1.01 (0.997–1.03)1.03 (1.01–1.04)d
Severe cranial ultrasound abnormalitye2.71 (1.28–5.71)d9.87 (4.40–22.17)f6.69 (2.78–16.09)f
Indomethacin0.59 (0.30–1.14)1.40 (0.59–3.31)0.60 (0.30–1.20)
Ligation of PDA1.46 (0.76–2.81)1.39 (0.63–3.08)1.91 (0.96–3.77)
Postnatal steroid therapy1.28 (0.63–2.62)2.28 (0.90–5.77)1.62 (0.77–3.40)
  • a Cerebral palsy, blindness, or deafness.

  • b MDI of <70 and/or neurosensory abnormality.

  • c P < .05.

  • d P < .01.

  • e Including grade III or IV bleeding, periventricular hemorrhage, or ventricular dilation at discharge.

  • f P < .001.